Weiss Ratings Reiterates "Sell (E+)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings in a report issued on Saturday, May 24th,Weiss Ratings reports.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Chardan Capital cut their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group lowered their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Down 2.7%

Shares of 4D Molecular Therapeutics stock traded down $0.10 during trading on Friday, reaching $3.61. The company's stock had a trading volume of 457,093 shares, compared to its average volume of 833,623. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93. The company has a market cap of $167.23 million, a price-to-earnings ratio of -1.27 and a beta of 2.87. The firm's 50-day moving average is $3.23 and its two-hundred day moving average is $4.78.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). On average, equities research analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. BVF Inc. IL raised its holdings in 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after purchasing an additional 1,890,647 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after acquiring an additional 92,791 shares in the last quarter. Millennium Management LLC lifted its position in 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after acquiring an additional 213,264 shares during the period. Federated Hermes Inc. grew its holdings in 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after purchasing an additional 1,246,419 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after purchasing an additional 504,086 shares during the period. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.